<?xml version="1.0" encoding="UTF-8"?>
<p>A randomized controlled trial (RCT) of MC and rosiglitazone treatment in NIDDM patients reveals that rosiglitazone treatment can elevate the serum sialic acid, which is associated with diabetes and complications, while MC group keeps it comparable to normal subjects [
 <xref rid="B103" ref-type="bibr">103</xref>]. Similarly, a 4-week, double-blind RCT evaluates the efficacy of bitter melon pulp powder and metformin in newly diagnosed T2DM patients, and, conclusively, bitter melon has moderate hypoglycemic effect [
 <xref rid="B104" ref-type="bibr">104</xref>]. Furthermore, a RCT comparing the different effects of bitter melon and glibenclamide concludes that the hypoglycemic effect of bitter melon is inferior to that of glibenclamide, but bitter melon can ameliorate the diabetes-related cardiovascular risk factors more effectively [
 <xref rid="B105" ref-type="bibr">105</xref>]. Another double-blind RCT in 24 T2DM cases illustrates that MC administration for three months lowers the HbA1c, 2 h glucose, glucose AUC, and mass index and elevates the insulin secretion obviously [
 <xref rid="B106" ref-type="bibr">106</xref>].
</p>
